Outset Medical reported second-quarter 2026 revenue of $31.6 million, up 1% year-over-year and 14% sequentially. The dialysis technology company's non-GAAP gross margin improved to 42.2%, up over 380 basis points from the previous year. The company secured a $40 million refresh agreement with HCA Healthcare extending through 2028, providing enhanced revenue visibility. Product revenue declined 5% year-over-year to $21.9 million, whilst service and other revenue grew 17% to $9.7 million. Outset completed its highest number of new site implementations in several years. One Texas system trained over 100 nurses and supported 956 treatments in the first 60 days. The company ended the quarter with $151 million in cash and reiterated full-year 2026 revenue guidance of $125 million to $130 million. It expects to use less than $40 million in cash for the full year.

Outset Medical, Inc. (NASDAQ: OM) investor alert: possible false statements, over $50 million in insider sales. Classactionlawyers advise Outset Medical, Inc. (NASDAQ: OM) investors that the firm is investigating potential legal claims arising from alleged false statements about FDA clearance requirements for one of the company's key products and demand for its dialysis machines. On March 30, 2026, U.S. District Judge Edward J. Davila ruled that key claims in a securities fraud lawsuit against Outset Medical and its CEO and former CFO will move forward. The lawsuit alleges that between September 2020 and August 2024, the company misled investors by describing TabloCart as a non-medical accessory and later touting customer demand for Tablo dialysis systems, despite knowing that TabloCart required clearance from the U.S. Food and Drug Administration and that demand for Tablo was weakening. These statements allegedly caused Outset Medical's stock to trade at artificially inflated prices. Judge Davila found the complaint sufficiently alleged that defendants acted with scienter, or an intent to deceive, in making these false and misleading statements. During this period, company insiders sold over $50 million in stock. After the full truth came out in August 2024, when the company reported disappointing second quarter 2024 results, the stock price fell 68%. Classactionlawyers is investigating potential wrongdoing by Outset Medical's directors and officers in connection with these allegations. If you own Outset Medical stock and wish to obtain additional information about your legal rights, please fill out the form below.